openPR Logo
Press release

Syndromes of Progressive Ataxia and Weakness Disorders Market to Witness Exponential Growth by 2020

Syndromes of Progressive Ataxia and Weakness Disorders Market

Ataxia is a neurological condition, characterized by lack of voluntary coordination of muscle movement. Ataxia causes head trauma, stroke, Transient Ischemic Attack (TIA), tumor and toxic reaction. Progressive ataxia and weakness disorders are related to damage, degeneration or loss of neurons of the brain which leads to muscle coordination disability.

A sample of this report is available upon request @ https://www.persistencemarketresearch.com/samples/2834

The global market for treatments of syndromes of progressive ataxia and weakness disorders is categorized based on various drugs used for treatment of progressive ataxia syndromes, drugs for progressive weakness syndromes and by technology. The progressive ataxia syndrome segment is further sub-segmented into major diseases, such as Friedreich's ataxia, Gertsman-Straussler-Scheinker disease and Machado-Joseph disease. The progressive weakness syndrome segment includes amyotrophic lateral sclerosis, hereditary spastic paraplegia, hereditary neuropathies, progressive bulbar palsy and multiple sclerosis. The technology segment is further sub-segmented into small molecules based therapies and monoclonal antibody.

In terms of geography, the U.S. and Canada holds major market share of treatments for syndromes of progressive ataxia and weakness disorders market in North America. In Europe, Germany, France and the U.K are major markets for treatments of syndromes of progressive ataxia and weakness disorders.

Globally, treatments for syndromes of progressive ataxia and weakness disorders market are growing due to novel drug development and rapid technological advancement for treatment of progressive ataxia and weakness disorders. Some of the major technological advancement involved in growth of the market are protein mis-folding, gene mutation and stem cell therapy. In addition, increased collaborations between industry players for development of new therapies is a key trend for the market.

However, patent expiries of major drugs hampers growth of the treatments for syndromes of progressive ataxia and weakness disorders market. Moreover, stringent regulations and standard requires for approval process of new drugs impede growth of the treatments for syndromes of progressive ataxia and weakness disorders market. Several government agencies, such as FDA and European Medicines Agency, are responsible for the approval of every drug. In addition, the approval process takes a very long time to approve a specific drug.

To view TOC of this report is available upon request @ https://www.persistencemarketresearch.com/toc/2834

Some of the major companies operating in the treatment for syndromes of progressive ataxia and weakness disorders market are Abbott Laboratories, Acorda Therapeutics Inc., American Regent Inc., Baxter International Inc., Biogen Idec., Bristol-Myers Squibb, Cadila Healthcare Ltd., Eli Lilly and Company, Glaxosmilthkline Plc., Sanofi, Roche Holding Ltd., Pfizer Inc. and Novartis AG.

About Us
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Contact Us
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Syndromes of Progressive Ataxia and Weakness Disorders Market to Witness Exponential Growth by 2020 here

News-ID: 703860 • Views: 194

More Releases from Persistence Market Research Pvt.Ltd

Global Food Fiber Market is forecast to expand at a CAGR of 5.7% from 2017 to 20 …
Some of the prominent players operating in the global food fiber market are J. RETTENMAIER & SÖHNE GmbH, Co KG, Kerry Group, Grain Processing Corporation, Nexira, SunOpta, Inc., Ingredion Roquette Frères S.A., Archer-Daniels-Midland Company, Tate & Lyle plc, and Cargill, Inc., notes Persistence Market Research (PMR). Several of these players are investing on advanced fiber fortification technologies for developing innovative formulations that have a variety of functional health benefits, in
In Vitro Protein Expression Market Accounting for US$ 250 Mn in 2025
Persistence Market Research has come up with an analytical research publication titled “In Vitro Protein Expression Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025).” The comprehensive in vitro protein expression market research report focuses on various trends, developments, opportunities, restraints, drivers and challenges impacting the growth of the global in vitro protein expression market. These factors vary in magnitude in different regions for which a detailed analysis is covered in
Tert-Amyl Methyl Ether Market Estimated to Experience a Hike in Growth by 2025
Introduction Ether compounds such as MTBE, ETBE, TAEE and TAME are used in fuel especially in gasoline in order to improve the combustion properties of fuels. Among these compounds, Tert-Amyl Methyl Ether used as oxygenated additive for the gasoline. Tert-Amyl Methyl Ether, formula (CH3)3 CH2COCH3, is an organic compound, used in fuel to improve its octane number. TAME is generally produced through the catalytic reaction between methanol (MeOH) and the 2-methyl-2-butene
Radar Simulator Market Significant Profits Estimated to be Generated by 2025
Radar simulator market is on upward scale, owing to increase in adaptation of modern technologies for the training purpose in commercial and military aircrafts & ships. Radar simulator is either software solution or combination of both software and hardware. Radar simulators emulate various radars and initiate their working to provide users with an artificial and apt environment for radar training and functional/system testing. The software solutions can be installed in

All 5 Releases


More Releases for Ataxia

Friedreich Ataxia Drug Market Emerging Trends || Leading Players are Edison Phar …
The market study on the global Friedreich Ataxia Drug Market will include the entire ecosystem of the industry, covering five major regions namely North America, Europe, Asia Pacific, Latin America and Middle East & Africa, and the major countries falling under those regions. The study will feature estimates in terms of sales revenue and consumption from 2019 to 2026, at the global level and across the major regions mentioned above.
Ataxia Therapeutics Pipeline Analysis 2018 | Reata Pharmaceuticals, Inc., Voyage …
Ataxia is a type of movement disorder characterized by lack of muscle control or coordination of voluntary movements. Some of the symptoms observed in the patients with ataxia are poor coordination, change in speech, difficulty in swallowing, and unsteady walk. Download the sample report @ https://www.pharmaproff.com/request-sample/1078 The disease causes include head injury; stroke; autoimmune diseases, such as sarcoidosis and multiple sclerosis; paraneoplastic syndromes; and viral infections. The disease is also found in
Ataxia Market: Surge in Alcohol Abuse and Sedentary Life Style Bolsters the Atax …
The United States of America is marred by ataxia as more than 150,000 cases have been found in the U.S.  The surge in the ataxia cases can be attributed to the food habits and the sedentary life style. Deficiency of vitamin B-12 is termed as one of the prominent causes of ataxia. Further, slurred speech, nystagmus (involuntary back and forth eye movement), problem in eating and writing, difficulty walking and
Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Market Not …
Ataxia is a neurological condition, characterized by lack of voluntary coordination of muscle movement. Ataxia causes head trauma, stroke, Transient Ischemic Attack (TIA), tumor and toxic reaction. Progressive ataxia and weakness disorders are related to damage, degeneration or loss of neurons of the brain which leads to muscle coordination disability. The global market for treatments of syndromes of progressive ataxia and weakness disorders is categorized based on various drugs used for
Friedreich's Ataxia Therapeutics - Pipeline Analysis, Clinical Trials & Results, …
the Friedreich's ataxia therapeutics pipeline comprises approximately 17 drug candidates in different stages of development. Friedreich’s ataxia is an autosomal recessive inherited genetic disorder that progressively damages the nervous system. Its initial symptoms include ataxia, impaired muscle coordination and impaired speech. This results in development of dysarthria, scoliosis, heart diseases and diabetes, but does not affect cognitive function. According to the research findings, most of the drug candidates in Friedreich's ataxia
Friedreich Ataxia (Central Nervous System) pipeline landscape H-1 (2017) - MRH
Friedreich ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness, and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes. Request Free Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1063542 Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Friedreich Ataxia - Pipeline Review, H1